Pharmacovigilance & Drug Safety · Healthcare & Life Sciences
Should you build or buy Pharmacovigilance & Drug Safety Case Management?
Pharmacovigilance & Drug Safety Case Management software is the regulatory backbone for handling individual case safety reports (ICSRs), covering intake from all sources (clinical trials, spontaneous reports, literature), MedDRA coding, causality assessment, narrative generation, signal detection, and E2B(R3) submission to the FDA and EMA. Any company holding a marketing authorization is legally required to maintain a validated system meeting 21 CFR Part 11 and ICH E2B standards for this function.
The build-vs-buy decision for Pharmacovigilance & Drug Safety Case Management turns on the GxP validation barrier — which makes self-building a genuine compliance liability, not just an engineering challenge — and how much of the value you can extend through customization once a validated vendor platform is in place; the specifics of your drug portfolio complexity and appetite for regulatory inspection risk decide it.
Build it, buy it, or bridge?
When building makes sense
The build case for pharmacovigilance case management is narrow, and it's important to be precise about why. The regulatory requirement — GxP validation under 21 CFR Part 11, E2B(R3) submission format maintenance, MedDRA license compliance, and audit trails that can survive FDA or EMA inspection — creates a compliance liability that doesn't exist in most other enterprise software categories. No internal engineering team has shipped a production self-built PV case management system that satisfies the full regulatory scope expected of a marketing authorization holder. The closest honest framing of a build scenario is not replacing a validated vendor platform but extending one: a company with strong PV data science capabilities might build proprietary signal analytics layers, custom MedDRA coding automation, or narrative generation workflows that sit on top of a vendor system handling the regulatory scaffold. Those extensions can capture real value — better signal sensitivity for a specific drug class, faster case narratives — without taking on the compliance liability of the underlying infrastructure. That's genuinely a build decision, but it's a build atop a vendor base, not instead of one.
When buying makes sense
Every marketing authorization holder buys a pharmacovigilance case management platform. The regulatory obligation makes this category unlike most software decisions — the question is which platform, not whether to buy. The platforms that dominate (ArisGlobal LifeSphere Safety, Oracle Argus Safety, Veeva Vault Safety) have each been through multiple FDA and EMA inspections, maintain current E2B(R3) submission templates as regulatory guidance updates, and carry GxP validation documentation that an internal build couldn't replicate without years of compliance work. For companies evaluating which platform to buy, the differentiating factors are increasingly about AI: Veeva's 2026 AI agent features for narrative generation and MedDRA coding suggestions are becoming table stakes rather than premium add-ons, and the depth of EMA versus FDA submission template maintenance matters for companies with multi-region portfolios. The vendor market for core PV case management is mature and the compliance case for buying is essentially absolute.
The desk read
GxP validation requirements make pharmacovigilance case management categorically different from most enterprise software decisions. Any system that touches ICSR intake, MedDRA coding, or E2B(R3) regulatory submission must be validated under 21 CFR Part 11 and maintain audit trails that can survive FDA or EMA inspection. No internal engineering team has shipped a production self-built pharmacovigilance system that meets that compliance bar at full regulatory scope.
Within the vendor landscape, the decision shifts to which platform's AI agent features in 2026 actually reduce case processing time without introducing coding errors. Veeva Vault Safety and ArisGlobal LifeSphere Safety have both invested in AI-assisted narrative generation and MedDRA coding suggestions, and those features are becoming table stakes rather than differentiators. For marketing authorization holders evaluating vendors, signal detection accuracy by drug class and the depth of EMA/FDA submission template maintenance are the factors that separate platforms at the margin.
Frequently asked
What is Pharmacovigilance & Drug Safety Case Management software?
Pharmacovigilance & Drug Safety Case Management software is the regulatory backbone for handling individual case safety reports (ICSRs), covering intake from all sources (clinical trials, spontaneous reports, literature), MedDRA coding, causality assessment, narrative generation, signal detection, and E2B(R3) submission to the FDA and EMA. Any company holding a marketing authorization is legally required to maintain a validated system meeting 21 CFR Part 11 and ICH E2B standards for this function.
When does building Pharmacovigilance & Drug Safety Case Management make sense?
Strictly speaking, building the core PV system from scratch is not viable today — GxP validation requirements and regulatory inspection readiness are prohibitive for any internal engineering team. The build decision that makes sense is extending a vendor platform with proprietary signal analytics or AI-assisted case processing workflows layered on top of the validated base.
When does buying Pharmacovigilance & Drug Safety Case Management make sense?
Every marketing authorization holder buys a validated PV platform — the regulatory obligation makes this effectively non-optional. The decision is which platform, with key factors being AI-assisted MedDRA coding and narrative generation features, multi-region submission template maintenance, and the platform's track record in FDA and EMA inspections.
What are the main Pharmacovigilance & Drug Safety Case Management vendors?
Representative vendors include ArisGlobal LifeSphere Safety, Oracle Argus Safety, Veeva Vault Safety, RxLogix PV Signal. B4 Pro scores the full set.
What does GxP validation mean for PV software and why does it matter?
GxP validation is the documented process of confirming that a system is fit for its regulated purpose, following FDA's 21 CFR Part 11 requirements for electronic records and audit trails. For PV software, it means every case processing action, coding decision, and submission must be traceable, reproducible, and auditable — and the validation package itself must survive regulatory inspection. Vendor platforms arrive with existing validation documentation; self-built systems require building that documentation from scratch, which is a years-long undertaking.